Addition of panitumumab to FOLFOXIRI improves response rates in colorectal cancer subtype

Adding panitumumab to FOLFOXIRI chemotherapy improved rates of overall response and secondary resection of metastases among patients with RAS wild-type metastatic colorectal cancer, according to results of the randomized phase 2 VOLFI trial published in Journal of Clinical Oncology.Further research is needed to determine whether the regimen, which serves as a new first-line treatment option for selected and fit patients, extends survival, according to researchers.“Chemotherapeutic doublet regimens combined with monoclonal antibodies represent the standard of care in untreated metastaticRead More

Share on facebook
Share on twitter
Share on linkedin